{"groups":[{"description":"Cohort 1, Dose Level 1 - Lenalidomide 25mg by mouth (PO) was given on days 1 to 10, plus, etoposide phosphate, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). During cycle 1, Etoposide 50mg/m\\^2/day, Vincristine 0.4 mg/m\\^2 /day, and Doxorubicin 10 mg /m\\^2/day were given as continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide, Vincristine 0.4 mg/m\\^2 /day, and Doxorubicin were given as continuous intravenous infusion days 1 to 4. During cycles 2-6, doses of etoposide and doxorubicin were adjusted based on hematologic parameters during the previous cycle. During cycle 1, Prednisone 60 mg/m\\^2 /day PO days 6 to 10. During cycles 2-6, Prednisone 60 mg/m\\^2 /day PO days 1-5. During cycle 1, Cyclophosphamide 750 mg/m\\^2 was given on day 10. During cycles 2-6, Cyclophosphamide 750 mg/m\\^2 was given on day 5. Rituximab was administered on day 4 prior to the start of EPOCH during cycle 1 and on day 1 during cycles 2 to 6.","id":"FG000","title":"Lenalidomide+Etoposide Phosphate, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin & Rituximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Did not complete last cycle of EPOCH-R2 due to progressive disease."}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"Received specified dose"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"Underwent screening/staging"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"Evaluated for response"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"Off treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"Off study"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"Disease progression on study"},{"achievements":[{"groupId":"FG000","numSubjects":"5"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Phase I - Safety & Tolerability"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Refused further treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"Received specified dose"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"Evaluated for response"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"Off treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"Off study"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"Disease progression on study"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Phase II - Recommended Phase 2 Dose"}]}